Introduction: The Evolution of Understanding Modic Changes

Chronic low back pain (CLBP) affects approximately one billion people globally and remains among the leading causes of years lived with disability. For decades, CLBP was understood primarily through biomechanical models—focusing on disc herniation, spinal stenosis, and structural degeneration. However, this mechanical paradigm could not explain a troubling paradox: many patients with pathological imaging findings experience minimal pain, while others with subtle structural findings suffer from disabling symptoms.

Over the past 30 years, experts have increasingly turned toward the biopsychosocial explanatory model as the predominant paradigm.

The discovery of Modic changes (MC) provided a critical piece of this puzzle and challenged purely psychosocial explanations as the sole driver of chronic back pain. Perhaps for this reason, Modic changes were often neglected in clinical practice for many years. Only in the 2010s—when robust epidemiological studies demonstrated a strong correlation between MC and pain severity—did Modic research gain prominence in spine medicine.

Most recently, we have been witnessing yet another paradigm shift. Newer and more sophisticated microbiological and imaging technologies have provided compelling evidence that Modic Type 1 changes may be driven by low-virulence bacterial infection within the intervertebral disc. This so-called 'infection hypothesis' has significant clinical implications.

What Are Modic Changes?

Modic changes are focal areas of bone marrow oedema and inflammation within the vertebral endplates—the cartilaginous interface between the intervertebral disc and the vertebral body. Unlike universal age-related disc degeneration, Modic changes represent active pathology: inflammation, edema, and abnormal bone formation that correlate strongly with pain severity and functional disability.

Classification System

Modic's original 1988 classification identified two distinct types based on MR signal characteristics:

Modic Type 1 (MC-1): Active Inflammation

MC-1 changes appear hypointense (dark) on T1-weighted MR and hyperintense (bright) on T2-weighted sequences, indicating edema and active inflammation. Type 1 changes are the most clinically significant and most painful subtype, associated with:

• Higher pain intensity (typically 6–8/10 on visual analog scale)
• Greater functional disability
• Longer symptom duration
• Worse quality-of-life measures
• Greatest responsiveness to medical intervention

Modic Type 2 (MC-2): Chronic Fatty Degeneration

MC-2 changes appear hyperintense on both T1- and T2-weighted sequences, indicating fatty infiltration of bone marrow. Type 2 changes represent approximately 50–60% of all Modic cases and typically develop after prolonged Type 1 inflammation.

The Bacterial Infection Hypothesis: From Controversy to Evidence

Historical Development of the Hypothesis

In 2008, researchers from Denmark proposed a novel hypothesis: that Modic Type 1 changes might result from low-virulence bacterial infection within the intervertebral disc, rather than purely inflammatory or mechanical processes. This hypothesis arose from observations that certain bacterial species—particularly Cutibacterium acnes—had been identified in disc tissue from patients with degenerative conditions.

Resolution of the Contamination Debate

Recent comprehensive reviews and methodologically rigorous studies have substantially resolved this debate in favour of true infection. When stringent microbiological criteria are applied, the evidence becomes compelling:

Quantitative Microbiology: Studies employing correct quantitative methods identified bacteria in approximately 40% of disc samples, with C. acnes present in 36% of total samples.

Histological Visualization: Fluorescence in situ hybridization (FISH) studies—which directly visualize bacterial aggregates within tissue—have identified small, irregularly distributed bacterial colonies embedded in disc tissue, accompanied by host inflammatory cells.

Antibiotic Treatment for Modic Type 1 Changes

Rationale for Antibiotic Treatment

If Modic Type 1 changes are driven by bacterial infection, then antibiotics represent a logical therapeutic approach. This logic is supported by randomized, double-blind, placebo-controlled trials that demonstrated significant and sustained pain relief following antibiotic therapy.

Clinical Trial Results

The Danish RCT (2013): Published in European Spine Journal, this trial demonstrated that 100 days of treatment with amoxicillin-clavulanate resulted in significant and sustained pain relief in patients with chronic low back pain and Modic Type 1 changes. Over 40% of patients achieved clinically significant improvement.

PP353: Intradiscal Antibiotic Injection (Linezolid)

PP353 is an intradiscal injection of linezolid, developed by Persica Pharmaceuticals Ltd (co-founded by this author's group). PP353 Phase 1b trial results (published in eClinicalMedicine – The Lancet, 2026) showed promising results regarding safety and efficacy in patients with chronic low back pain and Modic Type 1 changes.

Future Perspectives and Clinical Implications

If the bacterial infection hypothesis holds true, it will fundamentally alter our approach to chronic back pain. The implications include:

• Patients with unexplained chronic low back pain should be routinely screened for Modic Type 1 on MRI
• MRI-documented Modic Type 1 changes in an appropriate clinical context may warrant disc tissue sampling for microbiological diagnosis
• Antibiotics (either systemic or intradiscal) will become a first-line treatment for a previously refractory patient population
• Early intervention may prevent progression from MC-1 to MC-2 and secondary chronic degeneration

The bacterial infection hypothesis for Modic Type 1 changes represents an exciting paradigm shift within spinal orthopaedics and medicine more broadly. With increasing microbiological and immunological evidence, coupled with promising clinical trial results, antibiotic-based treatment is likely to become more central to managing an important subset of chronic low back pain patients in the years ahead.